FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and may be used for treating patients with hypertension and lipid storage disease. There is applied a combined drug containing dihydropyridine, calcium canal blockers, and statin, a hypolipidemic agent. The drug is prepared in such a manner that release rate of said ingredients can be controlled with respect to each other.
EFFECT: method allows higher clinical effectiveness and compliance, prevented antagonist and side effects of the combined therapy.
27 cl, 12 tbl, 10 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COFORMULATED DRUG FOR CARDIOVASCULAR DISEASES BASED ON CHRONOTHERAPY THERAPY | 2007 |
|
RU2464014C2 |
| CONTROLLED RELEASE COMPLEX PHARMACEUTICAL COMPOSITION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKERS AND HYDROXIMETHYLGLUTARYL-COA REDUCTASE INHIBITORS | 2007 |
|
RU2453307C2 |
| PHARMACEUTICAL COMBINED COMPOSITION | 2016 |
|
RU2736942C2 |
| COMPLEX MEDICINAL FORM OF 3-HYDROXY-3-METHYLGLUTARYL-CoA-REDUCTASE INHIBITOR I HYPOTENSIVE AGENT AND METHOD FOR PREPARING THEREOF | 2005 |
|
RU2381798C2 |
| STABLE PHARMACEUTICAL PREPARATION CONTAINING AMLODIPINE BENZYLATE AND ATENOLOL | 1998 |
|
RU2188636C2 |
| MULTI-LAYERED TABLET, CONTAINING EFFERVESCENT LAYER | 2010 |
|
RU2547562C2 |
| PHARMACEUTICAL COMPLEX FORMULATION COMPRISING ANGIOTENSIN II RECEPTOR BLOCKER AND HMG-CoA REDUCTASE INHIBITOR | 2014 |
|
RU2662565C2 |
| COMBINED COMPOSITION CONTAINING METFORMIN OF SUSTAINED RELEASE AND INHIBITOR HMG-CoA-REDUCTASE OF IMMEDIATE RELEASE | 2014 |
|
RU2651460C2 |
| PHARMACEUTICAL COMBINATION FORMULATION CONTAINING AMLODIPINE, LOSARTAN AND ROSUVASTATIN | 2014 |
|
RU2660586C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING AMLODIPINE AND LOSARTAN | 2007 |
|
RU2401107C2 |
